BUZZ-H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression
I'm PortAI, I can summarize articles.
H.C. Wainwright upgrades Lyell Immunopharma to 'buy', raising the price target to $45 due to promising cell therapy advancements. Ronde-cel shows 18-month progression-free survival for lymphoma, while LYL273 demonstrates significant potential in colorectal cancer with a 67% response rate. The market underestimates LYL273's potential in a multi-billion-dollar segment. Ronde-cel is undergoing trials for lymphoma treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments